Phase II Study of Ofatumumab in Elderly Patients With Chronic Lymphocytic Leukemia (CLL)

• Status: Active, not recruiting
• Trial end date: 0000-00-00
• Target enrollment: 34
• Participant gender: Both

Summary

The goal of this clinical research study is to learn if ofatumumab can help to control CLL. The safety of this drug will also be studied.

Ofatumumab is designed to bind to the surface of the leukemia cells . This may cause the leukemia cells to die.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborators: GlaxoSmithKline; National Comprehensive Cancer Network
• Treatments: Antibodies, Monoclonal
• Last Updated: 2016-12-14

Criteria

Inclusion Criteria:

1. Patients with chronic lymphocytic leukemia requiring treatment age >65 at the time of signing informed consent.

2. The Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status of 2-3.or patients with chronic lymphocytic leukemia requiring treatment age >65 years at the time of signing informed consent and ECOG/WHO performance status of 0-1 and a CIRS or Charlson co-morbidity score of 2 or higher.

3. Adequate renal and hepatic function (creatinine <2mg/dL and eGFR more than 30cc/minute, bilirubin <2mg/dL). Patients with renal or liver dysfunction due to organ infiltration by lymphocytes may be eligible after discussion with the study chairman. Patients with Gilbert's syndrome are eligible.

Exclusion Criteria:

1. Patients with documented prolymphocytic leukemia (prolymphocytes more than 55% in the blood).

2. Known positivity for HIV.

3. Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HGsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded.

4. Prior treatment for chronic lymphocytic leukemia.

5. Concurrent chemotherapy, radiotherapy, or immunotherapy, including other monoclonal antibodies. Localized radiotherapy to an area not compromising bone marrow function does not apply. Patients with malignancies with indolent behavior such as prostate cancer treated with radiation or surgery can be enrolled in the study as long as they have a reasonable expectation to have been cured with the treatment modality received.

6. Any serious medical condition, laboratory abnormality, or psychiatric illness that places the subject at unacceptable risk if he/she were to participate in the study.

7. Any known hypersensitivity to ofatumumab or its components.